Primobt

1 known investors

Primo Biotechnology develops next-generation radiopharmaceuticals for the diagnosis and treatment of severe and difficult-to-treat cancers, using a proprietary library of linker molecules and a radioisotope platform. The company pursues global market expansion through licensing partnerships with drug developers.